

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/575,671
				Filing Date	July 25, 2008
				First Named Inventor	Bradley T. Messmer
				Art Unit	1642
				Examiner Name	Sean E. Aeder
Sheet	1	of	2	Attorney Docket Number	50425/245

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	1	A copy of the International Search Report for PCT Application No. PCT/US2004/033176.	
	2	A copy of the Written Opinion of the International Searching Authority for PCT Application No. PCT/US2004/033176.	
	3	A copy of the International Preliminary Report on Patentability for PCT Application No. PCT/US2004/033176.	
	4	A copy of the Office Action for European Application No. 04 794 503.5, dated February 2, 2010.	
	5	A copy of the Office Action for European Application No. 04 794 503.5, dated April 9, 2008.	
	6	VALETTO et al. "Chronic Lymphoid Leukemia." Bio. and Clin. Invest. III, Abstract #1784, p. 431a.	
	7	FAIS et al. "Chronic Lymphocytic Leukemia B Cells Express Restricted Sets of Mutated and Unmutated Antigen Receptors." J. Clin. Invest. (1998), vol. 102, pp. 1515-25.	
	8	DAMLE et al. "Ig V Gene Mutation Status and CD38 Expression as Novel Prognostic Indicators in Chronic Lymphocytic Leukemia." Blood, Sept. 15, vol. 94, pp. 1840-47.	
	9	CHIORAZZI et al. "Immunoglobulin Variable Region Gene Characteristics and Surface Membrane Phenotype Define B-CLL Subgroups with Distinct Clinical Courses."	
		Chronic Lymphoid Leukemia, Marcel Dekker, New York, NY, US (2001) pp. 81-109.	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/575,671
				Filing Date	July 25, 2008
				First Named Inventor	Bradley T. Messmer
				Art Unit	1642
				Examiner Name	Sean E. Aeder
Sheet	1	of	2	Attorney Docket Number	50425/245

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	10	GHIOTTO et al. "Remarkably Similar Antigen Receptors Among a Subset of Patients with Chronic Lymphocytic Leukemia." J. of Clin. Invest. Vol. 113:7, pp. 1008-1011.	
	11	CARTER "Improving the Efficacy of Antibody-Based Cancer Therapies." Nature Reviews (2001) vol. 1, pp. 119-129.	
	12	CHIORAZZI et al. "B Cell Chronic Lymphocytic Leukemia: Lessons Learned from Studies of the B Cell Antigen Receptor." Annu. Rev. Immunol. 2005, 21:841-894.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.